GERN Share Price

Open 2.57 Change Price %
High 2.62 1 Day 0.02 0.78
Low 2.51 1 Week 0.15 6.20
Close 2.57 1 Month 0.30 13.22
Volume 2445367 1 Year -0.52 -16.83
52 Week High 3.16
52 Week Low 1.81
GERN Important Levels
Resistance 2 2.67
Resistance 1 2.63
Pivot 2.57
Support 1 2.51
Support 2 2.47
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
SIRI 5.11 -1.73%
STX 42.01 -16.83%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CMLS 0.28 21.74%
ZAZA 0.06 20.00%
CONN 17.50 18.24%
CONN 17.50 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Geron Corporation (NASDAQ: GERN)

GERN Technical Analysis 4
As on 26th Apr 2017 GERN Share Price closed @ 2.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.34 & Strong Buy for SHORT-TERM with Stoploss of 2.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
GERN Target for April
1st Target up-side 2.46
2nd Target up-side 2.59
3rd Target up-side 2.72
1st Target down-side 2.08
2nd Target down-side 1.95
3rd Target down-side 1.82
GERN Other Details
Segment EQ
Market Capital 171289824.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.geron.com
GERN Address
GERN
149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
United States
Phone: 650-473-7700
Fax: 650-473-7750
GERN Latest News
Analyst provided some recent clues on Geron Corporation (GERN) and Banc of ...   USA Commerce Daily   - 26th Apr 17
Geron Corporation (GERN) has current market capitalization of $405.86 Million   StandardOracle   - 26th Apr 17
Why to Keeping Eye on McDermott International, Inc. (MDR), Geron Corporation ...   StockNewsJournal   - 26th Apr 17
Geron 2017 Annual Meeting of Stockholders to be Held on May 9   GlobeNewswire (press release)   - 25th Apr 17
Staking A Claim To Geron   Seeking Alpha   - 17th Apr 17
Geron settling class-action securities suit for $6.25M   Seeking Alpha   - 11th Apr 17
Why Geron Corporation Stock Is Surging Higher Today   Motley Fool   - 10th Apr 17
Geron's Guiding Light   Seeking Alpha   - 06th Apr 17
Geron Corp (GERN) Announce Presentation at AACR on Non-Clinical Data for ...   StreetInsider.com   - 05th Apr 17
Geron Corporation (GERN) Soars 7.08% on March 27   Equities.com   - 28th Mar 17
Interactive Technical Analysis Chart Geron Corporation ( GERN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Geron Corporation
GERN Business Profile
Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.